Improved Glioblastoma Treatments Could Lie in Tumor Organoids
Glioblastoma organoids grown from patient tissue can be rapidly deployed to investigate personalized treatment approaches
Related Articles
Aptadir Therapeutics Pioneers RNA Inhibitors That Target Hypermethylation in Rare Genetic Disorders
Aptadir engineers RNA therapies that inhibit DNMT-1 to prevent methylation in genes associated with myelodysplastic syndrome and other disorders.
Recipharm and Exela Pharma Sciences Form Exclusive CDMO Strategic Alliance
The strategic collaboration will provide Recipharm with access to Exela’s manufacturing facility located in Lenoir, NC.
Improving the Downstream Processing of Biological Products
Industry, academic institutions, suppliers, and regulatory agencies working together can yield state-of-the-art downstream processes.
Process Development Accelerates with Multidisciplinary Teamwork
KBI Biopharma says they’re selecting the best technologies to fill gaps in their processes with grassroots help from their scientific staff.
IMAC-Based Protein Purification
Researchers recommend verifying success of column-based purification to confirm the presence and availability of the tag on target protein.
Quell Therapeutics Taps eXmoor Pharma to Manufacture CAR-Tregs
Quell’s proprietary platform has been developed to generate engineered CAR-Treg cell therapies that can be directed to specific tissues.
Roche-Poseida Lead Allogeneic CAR-T Advances after Showing Promise in Multiple Myeloma
Poseida Therapeutics’ lead allogeneic chimeric antigen receptor T-cell candidate it is co-developing with Roche will advance to Phase Ib.
Aptadir Therapeutics Pioneers RNA Inhibitors That Target Hypermethylation in Rare Genetic Disorders
Aptadir engineers RNA therapies that inhibit DNMT-1 to prevent methylation in genes associated with myelodysplastic syndrome and other disorders.
In a First, Complete Connectome of Every Neuron in the Drosophila Brain Mapped
The first wiring diagram of every neuron in an adult brain, and the 50 million connections between them, has been produced for Drosophila.
Roche-Poseida Lead Allogeneic CAR-T Advances after Showing Promise in Multiple Myeloma
Poseida Therapeutics’ lead allogeneic chimeric antigen receptor T-cell candidate it is co-developing with Roche will advance to Phase Ib.